![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Using Real World Data to Assess the Risk of Suicidality among Patients Initiating an Efavirenz versus an Efavirenz-Free Antiretroviral Regimen
|
|
|
Reported by Jules Levin
IDSA Oct 8-12 2014 Philadelphia, PA
Ella Nkhoma1*, John Coumbis2, Amanda Farr3, Stephen Johnston3, Bong Chul Chu3, Lisa Rosenblatt4, Daniel Seekins5, Angelina Villasis Keever5
1Bristol-Myers Squibb, Global Pharmacovigilance and Epidemiology, Wallingford, Connecticut, United States, 2Bristol-Myers Squibb, Global Pharmacovigilance and Epidemiology, Hopewell, New Jersey, United States, 3Truven Health Analytics, Bethesda, Maryland, United States, 4Bristol-Myers Squibb, Health Economics and Outcomes Research, Plainsboro, New Jersey, United States, 5Bristol-Myers Squibb, US Medical, Plainsboro, New Jersey, United States
*Disclosure for Ella Nkhoma: Employee, Bristol-Myers Squibb; no other disclosure
![IDSA1.gif](../images/101514/101514-10/IDSA1.gif)
![IDSA2.gif](../images/101514/101514-10/IDSA2.gif)
![IDSA3.gif](../images/101514/101514-10/IDSA3.gif)
![IDSA4.gif](../images/101514/101514-10/IDSA4.gif)
![IDSA5.gif](../images/101514/101514-10/IDSA5.gif)
![IDSA6.gif](../images/101514/101514-10/IDSA6.gif)
![IDSA7.gif](../images/101514/101514-10/IDSA7.gif)
![IDSA8.gif](../images/101514/101514-10/IDSA8.gif)
![IDSA9.gif](../images/101514/101514-10/IDSA9.gif)
![IDSA10.gif](../images/101514/101514-10/IDSA10.gif)
![IDSA11.gif](../images/101514/101514-10/IDSA11.gif)
![IDSA12.gif](../images/101514/101514-10/IDSA12.gif)
![IDSA13.gif](../images/101514/101514-10/IDSA13.gif)
![IDSA14.gif](../images/101514/101514-10/IDSA14.gif)
![IDSA15.gif](../images/101514/101514-10/IDSA15.gif)
![IDSA16.gif](../images/101514/101514-10/IDSA16.gif)
![IDSA17.gif](../images/101514/101514-10/IDSA17.gif)
![IDSA18.gif](../images/101514/101514-10/IDSA18.gif)
![IDSA19.gif](../images/101514/101514-10/IDSA19.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|